Nachrichten zur ABBVIE Aktie

AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.…

…

AbbVie to buy Landos to expand pipeline of immunity-related illnesses…

- Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis…

…

AbbVie executive sells over $3.7 million in company stock…

Am 15. September 2023 erschien der Alzheimer-Aktien-Report von André Fischer, der Biotech-Firmen behandelte, die sich auf die Bereiche Demenz, Parkinson…

Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez are included in this Analyst Blog.…

…

Todays Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AbbVie Inc. (ABBV) and Salesforce,…

Am US-amerikanischen Aktienmarkt liegt das Wertpapier von AbbVie aktuell im Minus. Die Aktie kostete zuletzt 179,37 US-Dollar. Heute hat sich…

…

Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…

Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…

Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast…

For Medical and Trade media. · Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease…

…

The FDA grants priority review status to Sanofis (SNY) and AbbVies (ABBV) sBLAs for Dupixent and Epkinly, respectively…

AbbVie and OSE Immunotherapeutics ink $713M deal…

Healthcare is one of the worlds most critical sectors, and healthcare stocks offer an opportunity to invest in companies that…

Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help…

AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports…

Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions…

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…

Robert Michael is set to succeed Richard A. Gonzalez as AbbVies (ABBV) CEO, effective Jul 1, 2024.…

Michael, who is AbbVies chief operating officer, will become the companys second-ever CEO since the company spun out from Abbott…

AbbVie names Robert A. Michael as new CEO…

…

AbbVie Inc.’s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of…

Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and…

The drugmaker is handling its biggest obstacle yet relatively well.…

The pharmaceutical industry is a major player in the life science sector, responsible for developing and manufacturing the majority of…

…

Heres what could happen to AbbVies shares next.…

…

Both offer above-average yields but which can deliver the most dividend income over the long run?…

Wien (www.aktiencheck.de) - AbbVie (ISIN: US00287Y1091, WKN: A1J84E, Ticker-Symbol: 4AB, NYSE-Symbol: ABBV) (+0,6%) stellte ebenfalls am Freitag seine Jahreszahlen vor,…